BCR and B-cell chronic lymphocytic leukemia: Such findings directly implicate the capacity of primary CLL cells to retain their ability to respond to antigen engagement in the presence of a covalent inhibitor of BTK (a key mediator of the BCR signal pathway) by modifying signaling to induce other downstream effectors critical to tumor biology.